15 / 32
FLAURA trial
•
Impressive results for osimertinib
•
Good CNS activity: baseline brain imaging was mandated only in patients with known or
suspected CNS metastases, with follow-up imaging in patients with confirmed CNS metastases
•
No data on patients with less common mutations (those in codons 18 and 20)
•
Trial conducted against gefitinib / erlotinib
•
OS not yet mature